Applied Biosystems Inc. and Asuragen, Inc., a provider of pharmacogenomic services, are collaborating with the Critical Path Institute’s Predictive Safety Testing Consortium (PSTC) to develop a predictive gene signature panel that will allow pharmaceutical companies to screen potential therapeutics quickly and easily for toxic effects in pre-clinical samples...